1	MWANGI AND OTHERS HUMAN MILK OLIGOSACCHARIDES AND MALARIA
2	Title: Sex-dependent associations between human milk oligosaccharides and malaria outcomes in
3	breastfeeding Ugandan children
4	Authors: Victor Irungu Mwangi ^{1,*} , Tonny Jimmy Owalla ² , Sara Moukarzel ^{3, 4} , Emmanuel Okurut ² , Chloe
5	Yonemitsu ³ , Lars Bode ^{3, 4} , and Thomas G. Egwang ²
6	
7	Author affiliations: ¹ Programa de Pós-Graduação em Medicina Tropical, Universidade do Estado do
8	Amazonas (UEA), Manaus, AM, Brazil; ² Med Biotech Laboratories, Kampala, Uganda; ³ Department of
9	Pediatrics, Division of Neonatology, University of California San Diego, La Jolla, California, United States
10	of America; ⁴ Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence (MOMI
11	CORE), University of California San Diego, La Jolla, California, United States of America.
12	
13	Key words
14	Human milk oligosaccharides, malaria, breastfeeding children
15	* Corresponding Author: <u>mwangiv@gmail.com;</u>
16	
17	Abstract
18	Human milk oligosaccharides (HMOs), whose compositions vary between secretor and non-secretor
19	mothers, protect breastfeeding children against various diseases. We investigated the relationship between
20	HMOs in Ugandan secretor mothers and malaria outcomes in their children. Malaria outcomes in
21	breastfeeding children followed up over seven months were classified as malaria-free and asymptomatic,
22	mild, or severe malaria. A single human milk sample collected from each mother was analyzed for HMOs.
23	Significantly higher 2'fucosyllactose (2'FL) and lacto-N-fucopentaose I (LNFP I) concentrations were
24	observed in mothers of malaria-free children, and significantly higher lacto-N-tetraose (LNT) concentrations

25 were observed in mothers of children with asymptomatic malaria. Concentrations of five HMOs, 3- $1 \mid P \mid a \mid g \mid e$

26	fucosyllactose (3 FL), 3'sialyllactose (3'SL), difucosyllactose (DFLac), lacto-N-fucopentaose II (LNFP II),
27	and sialyllacto-N-tetraose b (LSTb); and two HMOs, difucosyllacto-N-tetrose (DFLNT) and fucosyllacto-N-
28	hexaose (FLNH) were significantly higher in mothers of malaria-infected children and children with severe
29	malaria, respectively. Sex-dependent associations were observed for some HMOs.

- 30
- 31

Methods, Results & Discussion

Breastfeeding protects children against malaria by mechanisms which are poorly understood [1]. 32 Human milk oligosaccharides (HMOs), representing the third most abundant component of human milk, 33 protect breastfeeding children against diseases [2]. HMO concentrations vary between secretor and non-34 secretor mothers [3,4] who constitute approximately 80 % and 20 % of Ugandan mothers, respectively [5]. 35 Secretor mothers have an active fucosyltransferase 2 (FUT2) making their milk highly abundant in FUT-2 36 dependent HMOs like 2'-fucosyllactose (2'FL) and lacto-N-fucopentaose I (LNFP I); non-secretor mothers 37 with an inactive FUT2 have low milk concentrations of FUT2-dependent HMOs [1,2]. Here, we investigated 38 39 the relationship between HMOs in 99 Ugandan secretor mothers and malaria outcomes in their breastfeeding children (Supplementary Table 1). Non-secretor mother-child pairs were not included because of the small 40 sample size. Children were followed up between March and September 2018 for malaria infection and 41 clinical episodes during clinic visits. Malaria diagnosis was by CareStart malaria Pf (HRP-2) rapid diagnostic 42 test (Access Bio, NJ, USA). Malaria-free (MF) children were consistently malaria-negative during 8 clinic 43 visits for other ailments. Children with asymptomatic malaria (AM) were malaria-positive with no symptoms 44 or fever. Children with mild malaria (MM) were malaria-positive with non-specific symptoms like vomiting, 45 diarrhea, poor feeding and fever (\geq 37.5 °C). Finally, children with severe malaria (SM) were malaria-positive 46 with other symptoms including respiratory distress and severe anemia requiring blood transfusion according 47 to the World Health Organization definition [6]. Children with AM or MM received artemether-lumefantrine 48

49 (Coartem); those with SM received intravenous quinine or rectal artesunate according to national treatment
 50 guidelines.

51 A single human milk sample was collected from each mother in March 2018 and analyzed for 19 HMOs by high performance liquid chromatography (HPLC) as described [7]. Human milk was spiked with 52 raffinose as an internal standard. Absolute concentrations were calculated based on standard response curves 53 for each annotated HMO. The total concentration of HMOs was calculated as the sum of the annotated 54 oligosaccharides and the relative abundance of each HMO was calculated. HMO-bound fucose and HMO-55 bound sialic acid were calculated on a molar basis. Simpson's Diversity index was calculated based on 56 relative abundance of HMOs. Children with laboratory-confirmed malaria were designated malaria infected 57 (MI = AM + MM + SM; n = 35); and those who experienced clinical malaria were grouped as MM + SM (n = 19). 58 Associations between HMO concentrations and malaria outcomes in all children and separately in males and 59 females were assessed by the Mann-Whitney U and Welch t-tests. 60

We first compared HMOs between mothers of malaria-free (n=64) and malaria-infected (MF versus 61 62 MI) children. Higher 2'FL, LNFP I, total HMOs and HMO-bound fucose (HMO-Fuc) concentrations were observed in mothers of MF children (Figure 1A). Although LNFP I concentrations decrease during lactation 63 (5, 8), the median LNFP I concentration during late lactation was significantly higher in mothers of malaria-64 free children (1247.8 (537.4-2135.0) nmol/mL versus 450.0 (330.6-1417.2) nmol/mL; P = 0.006). By 65 contrast, higher 3'sialyllactose (3'SL), 3-fucosyllactose (3FL), difucosyllactose (DFLac), lacto-N-66 fucopentaose II (LNFP II) and sialyllacto-N-tetraose b (LSTb) concentrations and the diversity index 67 (reflecting variety in HMOs) were observed in mothers of MI children (Figure 1B). We next compared 68 HMOs between mothers of children with AM and children with clinical malaria (AM versus MM+SM). 69 70 Lacto-N-tetraose (LNT) concentrations were higher in mothers of AM children (Figure 1C; Supplementary Table 2). We then compared HMOs between mothers of children with mild malaria (MM) and children with 71 severe malaria (SM). Difucosyllacto-N-tetraose (DFLNT), fucosyllacto-N-hexaose (FLNH) and HMO-Fuc 72

concentrations were higher in mothers of SM children (Figure 1D, Supplementary Table 3). Finally, since
MF and AM outcomes might overlap, we compared HMOs between mothers of MF children and children
with AM. Diversity and LNT concentrations were higher in mothers of AM but not MF children while 2'FL,
LNFPI, total HMOs and HMO-Fuc concentrations were higher in mothers of MF but not AM children
(Figure 1E and F. Supplementary Table 4).

78 The relationships between HMOs and malaria outcomes were re-analyzed by children's sex. Higher 2'FL and HMO-Fuc concentrations in mothers of MF children were observed for females (Figure 2A). 79 Higher diversity and LSTb concentrations in mothers of MI children were observed for females, while higher 80 LNFP II concentrations in mothers of MI children were observed for males (Figure 2B). Second, higher LNT 81 concentrations in mothers of children with AM were observed for males while higher HMO-Fuc 82 concentrations in mothers of children with MM+SM were also observed for males (Figure 2C). Finally, 83 higher diversity and LNT concentrations in mothers of children with AM and higher LNFP I and HMO-Fuc 84 concentrations in mothers of MF children were observed for females (Figure 2D and E). The analyses for 85 all HMOs by sex are presented in **Supplementary Tables 5-7**. Analysis by sex was not done for malaria 86 severity because of small sample sizes. 87

It is remarkable that HMOs in milk collected at a single time point from mothers at different lactation 88 stages were associated with malaria outcomes in children during follow up. From published [8] and our own 89 studies [5], eight of these HMOs remain unchanged or increase in concentration throughout lactation. It is 90 plausible that the concentrations of these HMOs at the single sampling mirrored those in mothers during 91 follow up. Although LNFP I was reduced in late lactation [821.3 (373.8-1941.4) nmol/mL at > 6 months 92 versus 1586.7 (620.5-2475.0) nmol/mL at \leq 6 months; P = 0.048)], it was still associated with the malaria-93 free status. This raises the possibility that HMOs which decrease in early lactation may still have an effect 94 on disease risk in breastfeeding children in late lactation. 95

Our data confirm previous reports that fucose-bound HMOs protected children against infectious 96 diseases [1,2] and extends this protection to malaria. Concentrations of 2'FL and LNFP1, with an α 1-2 fucose 97 linkage, were significantly higher in mothers of malaria-free but not malaria-infected children. By contrast, 98 LNFPII and DFLac, with a1-3 and a1-4 fucose linkages, were significantly higher in mothers of malaria-99 infected children. Our data support previous reports linking higher concentrations of α 1-2-fucosylated HMOs 100 101 to a lower incidence of diarrhea [9,10], zero sick days [11] and lower infant mortality in HIV-exposed infants [12] and higher concentrations of α 1-3 fucosylated HMOs to sick days [11]. Moreover, significantly higher 102 concentrations of LNT in mothers of children with asymptomatic malaria suggest that it might be associated 103 104 with malaria clinical immunity. Additionally, high concentrations of DFLNT and FLNH were observed in mothers of children with severe but not mild malaria; previous studies have not reported associations between 105 HMOs and disease severity in children. Finally, significant differences in HMO concentrations between 106 mothers of children with asymptomatic malaria and malaria-free children (Figure 1E and F; Figure 2D and 107 **E**) suggest that these malaria outcomes do not overlap in this study. 108

To the best of our knowledge, this is the first study to report significant sex-dependent associations 109 between HMOs and malaria outcomes in children from a malaria-endemic region. However, the mechanisms 110 by which HMOs influence malaria outcomes in children in a sex-dependent manner remain unknown. Some 111 HMOs reach the systemic circulation after ingestion [13] where they engage innate immune cells implicated 112 113 in malaria protection and disease [14,15,16]. HMOs also act as soluble decoy receptors which pre-empt pathogen attachment to host cells [2]. Finally, HMOs induce specific microbiota which are important for the 114 development of immunity [2,17] and sex differences in microbiota composition [18] and innate immune 115 116 responses have been reported in malaria patients [19]. Mechanistic studies of HMOs and malaria outcomes in children must be undertaken to obtain useful insights about the mechanisms of breastfeeding-mediated 117 protection. 118

This study has several limitations. First, associations between HMO blood concentrations in children 119 and malaria outcomes were not investigated. Second, the sample sizes were small especially when malaria 120 121 outcomes were stratified by children's sex and disease severity. However, this limitation does not negate the 122 significant differences in concentrations and composition of HMOs between mothers of children with 123 different malaria outcomes. The confirmation of prior literature linking α 1-2-fucosylated HMOs and α 1-3or α 1-4-fucosylated HMOs to protection and disease in children [9, 10,11, 12] validates our findings. Third, 124 125 a single milk sample, rather than longitudinal milk samples, was collected from each mother at the same time 126 point for measuring HMO concentrations. This limitation is mitigated by the observed significant 127 associations between HMO concentrations and malaria outcomes in children and the fact that the concentrations of eight of these HMOs remain constant or increase during lactation (8). Fourth, the malaria-128 free status was not confirmed by a more sensitive molecular diagnostic test to distinguish it from 129 130 asymptomatic malaria with low parasitemias. However, comparisons of LNT, 2'FL and LNFP I 131 concentrations between mothers of malaria-free children and children with asymptomatic malaria suggest that these malaria outcomes do not overlap. Finally, our results are not generalizable to children of non-132 133 secretor mothers with different HMO concentrations and composition [3,4]. These limitations will be addressed in future longitudinal studies of breastfeeding secretor and non-secretor mother-child pairs. 134

In conclusion, our observational study demonstrated significant sex-dependent associations between malaria outcomes in breastfed children with concentrations of α 1-2-fucosylated HMOs, α 1-3- or α 1-4fucosylated HMOs, and sialylated HMOs in milk of Ugandan secretor mothers.

Ethical Consideration: The Uganda National Council for Science and Technology and the Research Ethics Committee of the Vector Division, Ministry of Health, approved the original HD4MC study. All mothers who donated milk samples and brought infants to the study clinic for malaria monitoring and health assessment signed or thumb-printed an informed consent form.

- Acknowledgements: We are grateful to the Ugandan mother-children pairs for their participation.
 We would like to thank the clinical and laboratory staff of Med Biotech Laboratories at St Anne HC III,
 Usuk subcounty in Katakwi District, Uganda.
- Financial support: Thomas Egwang received funding from the Global Innovation Fund and Grand Challenges Canada. Lars Bode is UC San Diego Chair of Collaborative Human Milk Research endowed by the Family Larsson-Rosenquist Foundation (FLRF), Switzerland. The funders played no role in the study design, data collection and analysis nor in the preparation of the manuscript and decision to publish this paper.
- Authors' Current addresses: Victor Irungu Mwangi: Programa de Pós-Graduação em Medicina 150 Tropical, Universidade do Estado do Amazonas (UEA), Manaus, AM, Brazil; Tonny Owalla, Emmanuel 151 152 Okurut, and Thomas G. Egwang: Med Biotech Laboratories, P.O. Box 9364, Kampala, Uganda; Sara 153 Moukarzel, Chloe Yonemitsu, and Lars Bode: University of California San Diego, La Jolla, California, United States of America. E-mail addresses: tgegwang@gmail.com, owallatonny@gmail.com, 154 155 okurutemmanuel1@gmail.com, mwangiv@gmail.com, cyonemit@ucsd.edu, smoukarzel@health.ucsd.edu, lbode@health.ucsd.edu. 156
- 157
- 158

159References

- Brazeau NF, Tabala M, Kiketa L, et al. Exclusive Breastfeeding and Clinical Malaria Risk in 6-Month Old Infants: A Cross-Sectional Study from Kinshasa, Democratic Republic of the Congo. *Am J Trop Med Hyg. 2016;95(4):827-830*
- 2. Bode L 2012. Human milk oligosaccharides: Every baby needs a sugar mama. *Glycobiology* 22 :1147–
 62.

- 165 3. Kunz C, Meyer C, Collado MC, et al. 2017. Influence of Gestational Age, Secretor, and Lewis Blood
- 166 Group Status on the Oligosaccharide Content of Human Milk. *J Pediatr Gastroenterol Nutr*. 64:789-98.
- 167 4. Totten SM, Zivkovic AM, Wu S, et al. 2012. Comprehensive profiles of human milk oligosaccharides
- 168 yield highly sensitive and specific markers for determining secretor status in lactating mothers. *J Proteome*
- 169 *Res.* 11:6124-33.
- 5. Owalla et al. 2023. The effect of non-genetic determinants of human milk oligosaccharide profiles in milk
 of Ugandan mothers. MS submitted.
- 6. Imbert P, Gérardin P, Rogier C, et al. 2002. Severe falciparum malaria in children: a comparative study of
- 173 1990 and 2000 WHO criteria for clinical presentation, prognosis and intensive care in Dakar, Senegal. *Trans*
- 174 *R Soc Trop Med Hyg.* 96:278-81.
- 175 7. Berger PK, Hampson HE, Schmidt KA, et al. 2023. Stability of Human-Milk Oligosaccharide
- 176 Concentrations Over 1 Week of Lactation and Over 6 Hours Following a Standard Meal. J Nutr.
 177 14;152:2727-33.
- 178 8. Plows JF, Berger PK, Jones RB, et al. 2021. Longitudinal Changes in Human Milk Oligosaccharides
- 179 (HMOs) Over the Course of 24 Months of Lactation. *J Nutr. 151:876-82*.
- 180 9. Newburg DS, Ruiz-Palacios GM, Altaye M, et al. 2004. Innate protection conferred by fucosylated
- 181 oligosaccharides of human milk against diarrhea in breastfed infants. *Glycobiology*. 14:253–63.
- 182 10. Morrow AL, Ruiz-Palacios GM, Altaye M, et al. 2004. Human milk oligosaccharide blood group epitopes
- and innate immune protection against campylobacter and calicivirus diarrhea in breastfed infants. Adv Exp
- 184 *Med Biol.* 554:443–46.
- 185 11. Davis JCC, Lewis ZT, Krishnan S, et al. 2017. Growth and Morbidity of Gambian Infants are
- 186 Influenced by Maternal Milk Oligosaccharides and Infant Gut Microbiota. Sci Rep. 7:40466.
- 187 12. Kuhn L, Kim H-Y, Hsiao L, et al. 2015. Oligosaccharide composition of breast milk influences survival
- of uninfected children born to HIV-infected mothers in Lusaka, Zambia. J Nutr. 145:66–72.

8 | P a g e

- 189 13. Goehring KC, Kennedy AD, Prieto PA, Buck RH. 2014. Direct evidence for the presence of human
- 190 milk oligosaccharides in the circulation of breastfed infants. *PLoS One.* 2014;9(7):e101692.
- 191 14. Triantis V, Bode L and van Neerven RJJ. 2018. Immunological Effects of Human Milk Oligosaccharides.
- 192 Front. Pediatr. 6:190.
- 193 15. Chua CL, Brown G, Hamilton JA, Rogerson S, Boeuf P. 2013. Monocytes and macrophages
- in malaria: protection or pathology? *Trends Parasitol.* 29:26-34.
- 195 16. Dobbs KR, Crabtree JN, Dent AE. 2020. Innate immunity to malaria-The role of monocytes.
- 196 Immunol Rev. 293:8-24.
- 197 17. Berger B, Porta N, Foata F, et al. 2020. Linking Human Milk Oligosaccharides, Infant Fecal
- 198 Community Types, and Later Risk To Require Antibiotics. *mBio*. 2020;11(2):e03196-19.
- 199 18. Valeri F, Endres K. 2021. How biological sex of the host shapes its gut microbiota. *Front* 200 *Neuroendocrinol.* 61:100912.
- 19. Kanoi BN, Egwang TG. 2021. Sex differences in concentrations of HMGB1 and numbers of
- pigmented monocytes in infants and young children with malaria. *Parasitol Int.* 84:102387.

203

Figure Legends

Figure 1. Associations between human milk oligosaccharides (HMOs) and malaria outcomes in children. A. Higher concentrations of α 1-2 fucose-linked HMOs, total and fucose-bound HMOs in mothers of malaria-free (MF) children. B. Higher concentrations of α 1-3- and α 1-4- fucose-linked HMOs and a sialylated HMO in mothers of malaria-infected (MI) children. C. Higher concentrations of LNT in mothers 9 | P a g e

of children with asymptomatic malaria (AM). **D**. Higher concentrations of DFLNT, FLNH and fucose-bound HMOs in mothers of children with severe malaria (SM). **E**. Higher diversity and concentrations of LNT in mothers of children with asymptomatic malaria. **F**. Higher concentrations of 2'FL, LNFP I and HMO-bound fucose in mothers of malaria-free children. Abbreviations: 2'FL, 2'fucosyllactose; LNFP I, lacto-N-fucopentaose I, 3'SL, 3'sialyllactose; DFLac, difucosyllactose; LNFPII, lacto-N-fucopentaose II (LNFP II), and LSTb, sialyllacto-*N*-tetraose b; LNT, lacto-N-tetraose; DFLNT, difucosyllacto-N-tetrose ; FLNH, fucosyllacto-N-hexaose; and Fuc HMO, HMO-bound fucose. Data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of HMO concentrations or diversity by malaria outcomes by either t-tests or Mann-Whitney U test. NS, non-significant; * Unadjusted P < 0.05; ****** Unadjusted P < 0.01.

Figure 2. Sex-dependent associations between HMOs and malaria outcomes in children. A. Higher concentrations of 2'FL and fucose-bound HMOs in milk of mothers of malaria-free (MF) female children. **B.** Higher diversity and concentrations of LNFP II and LSTb in mothers of malaria-infected (MI) male and female children, respectively. **C.** Higher concentrations of LNT and fucose-bound HMOs in mothers of mala children with asymptomatic (AM) and clinical malaria (MM+SM). **D.** Higher diversity and concentrations of LNT in mothers of AM female children. **E.** Higher concentrations of LNFP I, HMO-bound fucose and DSLNT in mothers of male and female children with MF status. Abbreviations: F, females; M, males. DSLNT, disialyllacto-N-tetraose; 2'FL, 2'fucosyllactose; LNFP I, lacto-N-fucopentaose I; LNFPII, lacto-N-fucopentaose II (LNFP II), and LSTb, sialyllacto-*N*-tetraose b; LNT, lacto-N-tetraose; Fuc HMO, HMO-bound fucose. Data are shown as box and whisker plots with the medians and the lower and upper quartiles or interquartile range (IQR). P values represent the outcomes of comparisons of HMO concentrations or diversity by malaria outcomes by either t-tests or Mann-Whitney U test. NS, non-significant; * Unadjusted P < 0.05; ****** Unadjusted P < 0.01.



Figure 2. Associations between HMOs and malaria outcomes in female and male children



Α

С







Figure 1: Associations between HMOs and malaria outcomes in all children